Monoclonal antibodies that target SARS-CoV-2 with high affinity are valuable for a wide
range of biomedical applications involving novel coronavirus disease (COVID-19) …

Monoclonal antibodies (mAbs) that are specific to SARS-CoV-2 can be useful in diagnosing,
preventing, and treating the coronavirus (COVID-19) illness. Strategies for the high …

The COVID-19 pandemic urgently needs therapeutic and prophylactic interventions. Here,
we report the rapid identification of SARS-CoV-2-neutralizing antibodies by high-throughput …

Despite development of effective SARS-CoV-2 vaccines, a sub-group of vaccine non-
responders depends on therapeutic antibodies or small-molecule drugs in cases of severe …

Neutralizing antibody is one of the most effective interventions for acute pathogenic
infection. Currently, over three million people have been identified for SARS-CoV-2 infection …

As the COVID-19 pandemic revealed, rapid development of vaccines and therapeutic
antibodies are crucial to guarantee a quick return to the status quo of society. In early 2020 …

Several antibody therapeutics have been developed against SARS-CoV-2; however, they
have attenuated neutralizing ability against variants. In this study, we generated multiple …

SARS-CoV-2 poses a public health threat for which therapeutic agents are urgently needed.
Herein, we report that high-throughput microfluidic screening of antigen-specific B-cells led …

Monoclonal antibodies are an efficacious therapy against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2). However, rapid viral mutagenesis led to escape …

The ongoing evolution of SARS-CoV-2 into more easily transmissible and infectious variants
has sparked concern over the continued effectiveness of existing therapeutic antibodies and …